Intellipharmaceutics International Inc. (IPCI)

[bluelucky]

Long time owner - first time poster here.

Thinking that the splits are 5% and 30%.

I think it was mentioned at one of the presentations that upon full commercialization of focalin the royalties could be as high as 8M. That would mean 20% of market capture of an 800M market. If split was 2.5% it would mean Par would have to capture 40% of the market and no way that could be envisioned.

5% is also consistent with the recent quarterly results. That would mean around 800,000 of focalin revenue based on 17M in quarterly sales. BTW I think the split during 25 and 35 exclusivity was 10%. I remember reading it is higher during exclusivity.

400,000 would then be from Seroquel. quarterly sales were 1.7M - take out say 500 for MNK costs and we have 1.2M - 30% is 400 roughly. The cost plus was accounted for I believe last quarter.

One question I have is we know future years will erode as more competitors hit the market. But what about capturing the immediate release market - That is a 6B a year market. I have to believe now that CR has gone generic the IR subscribers will begin switching. It will be interesting to keep an eye on that market as the months go by.

Fred - The symphony numbers are invaluable. Please keep them coming. Please also post the weekly focalin numbers. It will be helpful to keep an eye on those.

Having access to those numbers allows us to make more informed decisions. Too bad we need to get them through posters rather than the company.